Value Creation for Companies through LLS TAP:
Dollars & Beyond


Chris Takimoto (Chief Medical Officer of Forty Seven) comments on the benefits for TAP partners.

Please join The Leukemia & Lymphoma Society's (LLS) Therapy Acceleration Program® (TAP) leadership for a one hour virtual discussion panel with past and current TAP portfolio partners.


  • Introduction to the LLS TAP program
  • Moderated discussion with TAP Company representatives from:
    • argenx
    • BioTheryX
    • Constellation Pharmaceuticals
    • Kura Oncology
    • Kymera Therapeutics
    • X4 Pharmaceuticals
  • Q&A focused on the benefits TAP can provide to Portfolio Partners


Friday, Dec. 4, 2020

12 noon EST/9 am PST
via Zoom


Follow LLS